^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | izalontamab brengitecan (BL-B01D1) (Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate, HER3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC)
Excerpt:
...- Subjects must have been treated and refractory with 1 or more prior lines of applicable targeted therapy that is locally approved for the participant's genomic alteration at the time of screening; subjects who have tumors with EGFR L858R or Exon 19 deletion mutations must have received and be considered refractory to prior osimertinib therapy....
Source:
Title:
A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer
Excerpt:
...Initially treated locally advanced or metastatic non-small cell lung cancer patients with EGFR 19DEL or L858R mutation confirmed by histopathology and/or cytology; 6....
Trial ID:
Less C2 evidence
Source:
Title:
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
Published date:
05/31/2023
Excerpt:
BL-B01D1 demonstrated encouraging efficacy in heavily pretreated metastatic/locally advanced solid tumors, especially in pts with EGFRm NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.3001
Trial ID:
Source:
Title:
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
Published date:
05/25/2023
Excerpt:
NSCLC (EGFRmut) (n=34)...cPR...15...BL-B01D1 demonstrated encouraging efficacy in heavily pretreated metastatic/locally advanced solid tumors, especially in pts with EGFRm NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.3001
Trial ID:
